FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
Novartis plans to cut up to 550 jobs at Swiss facility
Novartis said on Tuesday up to 550 full-time jobs could be cut by the end of 2027 at the Swiss pharmaceutical company's Stein facility near Basel in northern Switzerland.
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 4:15 AM EST Company Participants Victor Bulto - President of US Angelika Jahreis - Global Head of Development Unit Immunology, Hepatology & Dermatology Richard Siegel Ingrid Zhang Patrick Horber - President of International Dianne Auclair Rocha Ruchira Glaser Shaun Coughlin Shreeram Aradhye - President of Development & Chief Medical Officer Shiva Malek Dushen Chetty Reshema Kemps-Polanco Fiona Marshall - President of BioMedical Research Norman Putzki - Global Program Head of Neuroscience Tracey Dawson Robert Baloh Aharon Gal - Chief Strategy & Growth Officer Harry Kirsch - Chief Financial Officer Vasant Narasimhan - Chief Executive Officer Steffen Lang - President of Operations Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Novartis AG (NVS) Shareholder/Analyst Call Transcript
Novartis AG ( NVS ) Shareholder/Analyst Call November 20, 2025 3:00 AM EST Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Michael Leuchten - Jefferies LLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
New, effective anti-malaria drug could help fight rising resistance, says Novartis
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial results.
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
Novartis AG ( NVS ) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Development & Chief Medical Officer Victor Bulto - President of US Angelika Jahreis Conference Call Participants Simon Baker - Rothschild & Co Redburn, Research Division Thibault Boutherin - Morgan Stanley, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Benjamin Jackson - Jefferies LLC, Research Division Sachin Jain - BofA Securities, Research Division Peter Verdult - BNP Paribas, Research Division Graham Parry James Quigley - Goldman Sachs Group, Inc., Research Division Presentation Operator Good morning and good afternoon, and welcome to the Novartis Immunology Portfolio Update Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Steve Scala - TD Cowen, Research Division Xue Chen - Barclays Bank PLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
